SCHEMBL21995640

SCHEMBL21995640

O=c1ccc(-c2cnc(Oc3cccc(F)c3)nc2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 4/20 0.49
CYP1A2 P05177 2/20 0.44
LMNA P02545 3/20 0.43
EGFR P00533 2/20 0.42
BTK Q06187 2/20 0.42
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
ACACB O00763 1/20 0.38
HTT P42858 1/20 0.38
PDE3B Q13370 3/20 0.38
PDE3A Q14432 3/20 0.38
TP53 P04637 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31674527 1.00 HPGDS (0.49) HPGDSCYP1A2LMNAEGFRBTK
SCHEMBL24155645 0.90 HPGDS (0.45) HPGDSCYP1A2LMNAEGFRBTK
SCHEMBL24155619 0.86 HPGDS (0.48) HPGDSCYP1A2LMNAEGFRBTK
SCHEMBL24155844 0.85 JAK2 (0.50) HPGDSCYP1A2LMNAEGFRBTK
SCHEMBL24155838 0.85 LMNA (0.49) HPGDSCYP1A2LMNAPDE4APDE4B
SCHEMBL21995641 0.85 HPGDS (0.61) HPGDSCYP1A2LMNAPDE4APDE4B
SCHEMBL24156317 0.83 HPGDS (0.46) HPGDSCYP1A2LMNAEGFRBTK
SCHEMBL24155856 0.82 CYP1A2 (0.46) HPGDSCYP1A2LMNAPDE4APDE4B
SCHEMBL24156307 0.81 HPGDS (0.47) HPGDSCYP1A2LMNAPDE4APDE4B
SCHEMBL24155869 0.80 MAPK14 (0.49) CYP1A2LMNAPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed
EP-3887358-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY Otsuka Pharmaceutical Co., Ltd. (JP) 2021-10-06 EP disclosed
CN-113166076-A Heterocyclic compounds for the treatment of epilepsy 大塚制药株式会社 2021-07-23 CN disclosed
WO-2020111263-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B HPGDS 1679/4885CYP1A2 203/4885LMNA 4384/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 HPGDS 1388/4885CYP1A2 181/4885LMNA 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.